The significance of natriuretic peptides in the evaluation of water-salt metabolism in chronic kidney disease


Cite item

Full Text

Abstract

The paper discusses the molecular, biochemical, and physiological properties of natriuretic peptides, including the clinical applications of their synthetic formulations, as well as the renal and extrarenal mechanisms of water-salt metabolism in chronic kidney disease.

Full Text

Значение натрийуретических пептидов в оценке водно-солевого обмена при хронической болезни почек. - Аннотация. Обсуждаются молекулярные, биохимические и физиологические свойства семейства натрийуретических пептидов, а также почечные и внепочечные механизмы регуляции водно-солевого обмена при хронической болезни почек, в том числе варианты клинического применения их синтезированных форм.
×

References

  1. Марина А.С., Кутина А.В., Наточин Ю.В. Физиологический анализ разных типов осмотического диуреза. Рос физиол журн им. И.М. Сеченова. 2011; 12: 1309-1318.
  2. Feller S.M., Gagelmann M., Forssman W.G. Urodilatin: A newly described member of the ANP family. Trends Pharmacol Sci 1989; 10 (3): 93-94.
  3. Елисеев О.М. Натрийуретические пептиды. Эволюция знаний. Тер арх 2003; 9: 40-45.
  4. Jamieson J.D., Palade G.E. Specific granules in atrial muscle cells. J Cell Biol 1964; 23: 151-172.
  5. De Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28 (1): 89-94.
  6. Kangawa K., Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 1984; 118 (1): 131-139.
  7. Yandle T.G. Biochemistry of natriuretic peptides. J Intern Med 1994; 235 (6): 561-576.
  8. Misono K.S., Fukumi H., Grammer R.T., Inagami T. Rat atrial natriuretic factor: complete amino acid sequence and disulfide linkage essential for biological activity. Biochem Biophys Res Commun 1984; 119 (2): 524-529.
  9. Dietz J.R., Scott D.Y., Landon C.S., Nazian S.J. Evidence supporting a physiological role for proANP-(1-30) in the regulation of renal excretion. Am J Physiol Regul Integr Comp Physiol 2001; 280 (5): R1510-1517.
  10. Espiner E.A. Physiology of natriuretic peptides. J Intern Med 1994; 235 (6): 527-541.
  11. Hodsman G.P., Phillips P.A., Ogawa K., Johnston C.I. Atrial natriuretic factor in normal man: effects of tilt, posture, exercise and haemorrhage. J Hypertens Suppl 1986; 4 (6): S503-S505.
  12. Manning P.T., Schwartz D., Katsube N.C. et al. Vasopressin-stimulated release of atriopeptin: endocrine antagonists in fluid homeostasis. Science 1985; 229 (4711): 395-397.
  13. Stasch J.P., Hirth-Dietrich C., Kazda S., Neuser D. Endothelin stimulates release of atrial natriuretic peptides in vitro and in vivo. Life Sci 1989; 45 (10): 869-875.
  14. Awazu M., Ichikawa I. Biological significance of atrial natriuretic peptide in the kidney. Nephron 1993; 63 (1): 1-14.
  15. Koller P.T., Grekin R.J., Nicklas J.M. Paradoxical response of plasma atrial natriuretic hormone to pericardiocentesis in cardiac tamponade. Am J Cardiol 1987; 59 (5): 491-492.
  16. Kalinowski L., Szczepańska-Konkel M., Jankowski M., Angielski S. Studies on potential involvement of protein kinase C in glomerular insensitivity to atrial natriuretic factor on low sodium intake. Med Sci Monit 2001; 7 (4): 628-634.
  17. Huang C.L., Lewicki J., Johnson L.K., Cogan M.G. Renal mechanism of action of rat atrial natriuretic factor. J Clin Invest 1985; 75 (2): 769-773.
  18. Golos M., Lewko B., Bryl E. et al. Effect of angiotensin II on ANP-dependent guanylyl cyclase activity in cultured mouse and rat podocytes. Kidney Blood Press Res 2002; 25 (5): 296-302.
  19. Закирова Н.Л., Кириченко А.А. Натрийурез и артериальная гипертония. Consilium Medicum 2011; 13: 5.
  20. de los Angeles Costa M., Elesgaray R., Loria A. et al. Atrial natriuretic peptide influence on nitric oxide system in kidney and heart. Regul Pept 2004; 118 (3): 151-157.
  21. Takezawa K., Cowley A.W., Skelton M., Roman R.J. Atriopeptin III alters renal medullary hemodynamics and the pressure-diuresis response in rats. Am J Physiol 1987; 252: F992-1002.
  22. Swärd K., Valsson F., Sellgren J., Ricksten S.E. Differential effects of human atrial natriuretic peptide and furosemide on glomerular filtration rate and renal oxygen consumption in humans. Intensive Care Med 2005; 31 (1): 79-85.
  23. Nakao K., Itoh H., Suga S. et al. The natriuretic peptide family. Curr Opin Nephrol Hypertens 1993; 2 (1): 45-50.
  24. Мухин Н.А., Фомин В.В. Ренин - мишень прямой фармакологической блокады при артериальной гипертонии. Тер арх 2009; 8: 5-9.
  25. Appel R.G. Growth-regulatory properties of atrial natriuretic factor. Am J Physiol 1992; 262: F911-918.
  26. Mitaka C., Hirata Y., Habuka K. et al. Atrial natriuretic peptide improves pulmonary gas exchange by reducing extravascular lung water in canine model with oleic acid-induced pulmonary edema. Crit Care Med 2002; 30 (7): 1570-1575.
  27. Koh G.Y., Klug M.G., Field L.J. Atrial natriuretic factor and transgenic mice. Hypertension 1993; 22 (4): 634-639.
  28. John S.W., Krege J.H., Oliver P.M. et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995; 267 (5198): 679-681.
  29. Hodgson-Zingman D.M., Karst M.L., Zingman L.V. et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med 2008; 359 (2): 158-165.
  30. McKie P.M., Cataliotti A., Huntley B.K. et al. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol 2009; 54 (11): 1024-1032.
  31. Joffy S., Rosner M.H. Natriuretic Peptides in ESRD. Am J Kidney Dis 2005; 46 (1): 1-10.
  32. Asakura M., Jiyoong K., Minamino T. et al. Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP). Circ J 2004; 68 (2): 95-100.
  33. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332 (6159): 78-81.
  34. Pedersen E.B., Pedersen H.B., Jensen K.T. Pulsatile secretion of atrial natriuretic peptide and brain natriuretic peptide in healthy humans. Clin Sci 1999; 97 (2): 201-206.
  35. Sawada Y., Suda M., Yokoyama H. et al. Stretch-induced hypertrophic growth of cardicytes and processing of braintype natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem 1997; 272: 20 545-20 554.
  36. Андреев Д.А., Рыкова М.С. Натрийуретические пептиды В-типа при сердечной недостаточности. Клин мед 2004; 6: 4-8.
  37. Козлов И.А., Харламова И.Е. Натрийуретические пептиды: биохимия, физиология, клиническое значение. Общая реаниматол 2009; 1: 89-97.
  38. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
  39. Mantymaa P., Vuolteenaho O., Marttila M., Ruskoaho H. Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology 1993; 133: 1470-1473.
  40. Harada M., Saito Y., Kuwahara K. et al. Interaction of myocytes and nonmyocytes is necessary for mechanical stretch to induce ANP/BNP production in cardiocyte culture. J Cardiovasc Pharmacol 1998; 31 (suppl): S357-359.
  41. Кошелева Н.А., Ребров А.П. Роль n-терминального фрагмента мозгового натрийуретического пептида у больных с хронической сердечной недостаточностью ишемического генеза. Клин мед 2011; 5: 26-29.
  42. Haug C., Metzele A., Kochs M. et al. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol 1993; 16 (7): 553-557.
  43. Бондарь И.А., Гражданкина Д.В. Роль мозгового натрийуретического пептида и его N-концевого предшественника в диагностике хронической сердечной недостаточности и бессимптомной дисфункции левого желудочка при сахарном диабете 2-го типа. Сахарный диабет 2011; 3: 31-35.
  44. Fried T.A., McCoy R.N., Osgood R.W., Stein J.H. Effect of atriopeptin II on determinants of glomerular filtration rate in the in vitro perfused dog glomerulus. Am J Physiol 1986; 250: F1119-F1122.
  45. Lai C.P., Egashira K., Tashiro H. et al. Beneficial effects of atrial natriuretic peptide on exercise-induced myocardial ischemia in patients with stable effort angina pectoris. Circulation 1993; 87 (1): 144-151.
  46. Моисеев B.C., Кобалава Ж.Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечнососудистых заболеваний). Клин фармакол тер 2002; 3: 16-18.
  47. McCullough P.A., Duc P., Omland T. et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41 (3): 571-579.
  48. Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 3: 7-15.
  49. Бугримова М.А., Савина Н.М., Ваниева О.С., Сидоренко Б.А. Бугримова М.А. Мозговой натрийуретический пептид как маркер и фактор прогноза при хронической сердечной недостаточности. Кардиология 2006; 1: 51-57.
  50. Dries D.L., Exner D.V., Domanski M.J. et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35 (3): 681-689.
  51. Kohse K., Feifel K., Mayer-Wehrstein R. Differential regulation of brain and atrial natriuretic peptides in hemodialysis patients. Clin Nephrol 1993; 40 (2): 83-90.
  52. Багрий А.Э. Сердечно-сосудистые нарушения при хронической почечной недостаточности. Тер арх 1998; 11: 80-83.
  53. Plum J., Grabensee B. Atrial natriuretic peptide in dialysis patients patients under various conditions of volume homeostasis. J Intern Med 1991; 229 (3): 209-216.
  54. Buckley M., Sethi D., Markandu N. et al. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent and dialysis-dependent chronic renal failure. Clin Sci 1992; 83 (4): 437-444.
  55. Полякова В.В., Команденко М.С. Особенности структурной перестройки миокарда на ранних стадиях развития почечной недостаточности. Нефрология 2003; 5 (3): 281-282.
  56. Longenecker J.C., Coresh J., Powe N.R. et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 2002; 13 (7): 1918-1927.
  57. Silver M.A., Maisel A., Yancy C.W. et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004; 10: 1-30.
  58. Zoccali C., Mallamaci F., Benedetto F. et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12 (7): 1508-1515.
  59. Nakatani T., Naganuma T., Masuda C. et al. Significance of brain natriuretic peptides in patients on continuous ambulatory peritoneal dialysis. Int J Mol Med 2002; 10 (4): 457-461.
  60. Chen H.H., Grantham J.A., Schirger J.A. et al. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 2000; 36 (5): 1706-1712.
  61. Chen H.H., Schirger J.A., Cataliotti A., Burnett J.C.Jr. Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. Eur J Heart Fail 2006; 8 (7): 681-686.
  62. Cataliotti A., Schirger J.A., Martin F.L. et al. Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation 2005; 112 (6): 836-840.
  63. Vogel M.W., Chen H.H. Novel natriuretic peptides: new compounds and new approaches. Curr Heart Fail Rep 2011; 8 (1): 22-27.
  64. Forssmann W., Meyer M., Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res 2001; 51 (3): 450-462.
  65. Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990; 168 (2): 863-870.
  66. Suresh M., Farrington K. Natriuretic peptides and the dialysis patient. Semin Dial 2005; 18 (5): 409-419.
  67. Komatsu Y., Nakao K., Suga S. et al. C-Type natriuretic peptide (CNP) in rats and humans. Endocrinology 1991; 129 (2): 1104-1106.
  68. Schirger J.A., Heublein D.M., Chen H.H. et al. Presence of Dendrosaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc 1999; 74: 126-130.
  69. Valentin J.P., Humphreys M.H. Urodilatin: a paracrine renal natriuretic peptide. Semin Nephrol 1993; 13 (1): 61-70.
  70. Heim J.M., Kiefersauer S., Fülle H.J., Gerzer R. Urodilatin and beta-ANF: binding properties and activation of particulate guanylate cyclase. Biochem Biophys Res Commun 1989; 163 (1): 37-41.
  71. Hildebrandt D.A., Mizelle H.L., Brands M.W., Hall J.E. Comparison of renal actions of urodilatin and atrial natriuretic peptide. Am J Physiol 1992; 262: R395-R399.
  72. Drummer C., Fiedler F., König A., Gerzer R. Urodilatin, a kidney-derived natriuretic factor, is excreted with a circadian rhythm and is stimulated by saline infusion in man. J Am Soc Nephrol 1991; 1 (9): 1109-1113.
  73. Lenz W., Herten M., Gerzer R., Drummer C. Regulation of natriuretic peptide (urodilatin) release in a human kidney cell line. Kidney Int 1999; 55 (1): 91-99.
  74. Luss H., Mitrovic V., Seferovic P.M. et al. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J 2008; 155 (6): 1012 e1-е8.
  75. Wang D.J., Dowling T.C., Meadows D. et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004; 110 (12): 1620-1625.
  76. Pan S., Chen H.H., Dickey D.M. et al. Biodesign of a renalprotective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci USA 2009; 106 (27): 11282-11287.
  77. Wei C.M., Kim C.H., Miller V.M., Burnett J.C.Jr. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 1993, 92 (4): 2048-2052.
  78. Schweitz H., Vigne P., Moinier D. et al. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 1992; 267 (20): 13928-13932.
  79. Lisy O., Huntley B.K., McCormick D.J. et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2008; 52 (1): 60-68.
  80. Dickey D.M., Burnett J.C.Jr., Potter L.R. Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 2008; 283 (50): 35003-35009.
  81. Lee C.Y., Chen H.H., Lisy O. et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009; 49 (6): 668-673.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies